Silk Technologies Board

brain-levyBrian Levy, O.D. M.Sc., Chairman – Dr. Levy brings more than three decades of ophthalmic industry expertise in the development of ophthalmic therapeutics. Recently, he was the Chief Medical Officer at Aerie Pharmaceuticals, a publicly traded ophthalmic pharmaceutical company focused on the discovery and development of medical innovations in ophthalmology. Previously, he has served multiple executive roles in both startup and Fortune 500 companies, including Chief Medical Officer at Bausch & Lomb. Dr. Levy earned a Doctor of Optometry degree from the University of California, Berkeley.

brian-lawrenceBrian D. Lawrence, Ph.D., CEO –  Dr. Lawrence is a co-founder of the company and co-inventor of the company’s functional technology. He has spent the last 10 years working on developing silk-derived materials for use in a variety of medical and commercial product applications. He earned his Ph.D. in Biomedical Engineering from Cornell University. Previously he worked in the chemical manufacturing industry and was involved with process engineering applications. He has authored over a dozen scientific publications and is co-inventor on 2 issued patents and 12 patent applications.

Alex Soltani, Board Member/Investor –  Alex Soltani Founded Skyview Capital in 2005 and is Chairman of the firm’s executive and investment committees. He is a serial entrepreneur. Prior to founding Skyview Capital, Mr. Soltani worked at Platinum Equity and operated All Digital Communications. Skyview Capital has completed over 30 transactions in the technology, software, and healthcare sectors. Mr. Soltani is very involved with the operations of the portfolio companies. Mr. Soltani holds a B.A. from UCLA.

Bill Mower, Board Member – Bill Mower has been helping clients solve problems and pursue opportunities with legal-related advice and counsel for more than 30 years and is a partner in Maslon’s Business & Securities Group. He represents a wide variety of clients in connection with mergers and acquisitions and management buy-outs. Bill counsels public companies in connection with their securities law compliance and general corporate matters and represents issuers and underwriters in connection with public and private securities offerings, secondary offerings, and alternative offerings. He also assists clients with their licensing and joint venture relationships and serves as de-facto general counsel to numerous public and private companies. Bill has real estate transactional experience and is a MSBA board certified real estate specialist in the State of Minnesota.

Emmett Cunningham, Jr., MD, PhD, MPH, Board Member – Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 350 publications.  Prior to joining Clarus, Dr. Cunningham was the Senior Vice President, Medical Strategy at Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET), where he helped build and lead the team that developed and commercialized Macugen, a first-in-class product for the treatment of age-related macular degeneration. Prior to Eyetech, Dr. Cunningham was at Pfizer, Inc (NYSE: PFE), where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. He is Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine, was Clinical Professor and Director of the Uveitis service at NYU from 2002 to 2005, and was Director of both the Uveitis Service and the Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001.   Dr. Cunningham received an MD and MPH in epidemiology and statistics from Johns Hopkins University and a PhD in neuroscience from the University of California at San Diego (UCSD) for work done at The Salk Institute.  


Christopher Aye, Board Member — Chris is a member of the Skyview Capital’s executive and investment committees. He is responsible for negotiating and structuring transactions, financial due diligence and ongoing oversight across the firm’s portfolio of investments. Mr. Aye has decades of experience in finance and accounting, including public audit, financial planning and analysis, mergers and acquisitions and private equity. Prior to joining Skyview, Mr. Aye served on various teams at Amgen, including the team that ran the successful $16 billion integration of Immunex Corp. Also at Amgen, Mr. Aye held the key role of Financial Planning & Analysis, where he effectively co-managed a $150 million annual operating expense budget. Prior to Amgen, Mr. Aye served as a Senior Analyst in the M&A Transactions Group at Homestore.com, where he focused on financial and operational due diligence on acquisition targets. Mr. Aye was a CPA with Arthur Anderson LLP as a Senior Associate in the High Technology Audit Group, where he successfully advised start-up and emerging middle market technology companies through strategic M&A and IPO transactions. Mr. Aye received a B.A. degree from the University of California, Santa Barbara, in Business Economics with a concentration in Accounting and his M.B.A. from the Marshall School of Business at the University of Southern California.

Paul M. Karpecki, OD, FAAO, Board Member — Dr Karpecki received his doctor of optometry degree from Indiana University and completed a fellowship in medical cornea and refractive surgery in Kansas City in affiliation with the Pennsylvania College of Optometry. He is currently the Director of corneal services and the Advanced OSD Clinic at the Kentucky Eye Institute. Dr. Karpecki was appointed to the Delphi International Society at Wilmer-Johns Hopkins, which included the top 25 dry eye experts in the world and the National Eye Institute’s Dry Eye Committee to provide insights around dry eye and women. He also co-chaired the Dry Eye Summit for the profession, was a director in the CJO Optometric Dry Eye Guidelines for EyeCare, was recently selected for the DEWS II Diagnostic sub-committee and most recently appointed co-chair of the Tear Film and Ocular Surface Society Symposium in 2016. He has over two decades experience in running some of the largest dedicated dry eye clinics in the US. A noted educator and author, Dr. Karpecki has provided over 1000 lectures. He has also authored over 1000 papers in journals, book chapters, clinical eblasts and newsletters. He currently serves as the Chief Clinical Editor for Review of Optometry and Chairs the New Technology and Treatment Conferences. He is also on the board for the charitable organization Optometry Giving Sight.


Medical Advisory Board

Richard L. Lindstrom, MD, Founding Partner of Minnesota Eye Consultants

Edward Holland, MD, Director of Cornea Services at Cincinnati Eye Institute

Terry Kim, MD, Professor of Ophthalmology at Duke University

Kelly Nichols, OD, MPH, PhD, FAAO, Dean of the University of Alabama at Birmingham School of Optometry

Tim Comstock, OD, MS, FAAO, Ophthalmic Industry Consultant